Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

doi:10.3390/healthcare1010096

Open AccessThis article is

freely available
re-usable

Healthcare 2013, 1(1), 96-99; doi:10.3390/healthcare1010096

Case Report

Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

Michael Z. Wang and Jerry D. Brewer *

Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

* Author to whom correspondence should be addressed.

Received: 20 August 2013; in revised form: 16 October 2013 / Accepted: 21 October 2013 / Published: 25 October 2013

Download PDF Full-Text [593 KB, uploaded 25 October 2013 15:06 CEST]

Abstract: No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.

Keywords: interleukin-2; melanoma; pulsed dye laser therapy

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Wang, M.Z.; Brewer, J.D. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.

AMA Style

Wang MZ, Brewer JD. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare. 2013; 1(1):96-99.

Chicago/Turabian Style

Wang, Michael Z.; Brewer, Jerry D. 2013. "Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser." Healthcare 1, no. 1: 96-99.

Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert